S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
S&P 500   5,251.58 (+0.06%)
DOW   39,762.49 (+0.01%)
QQQ   444.24 (-0.13%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.82 (+0.37%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.48 (+1.24%)
T   17.61 (+0.34%)
F   13.23 (+1.30%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.88 (-2.35%)
DIS   122.62 (+1.36%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.61 (+1.56%)
XOM   115.74 (+0.67%)
NASDAQ:RMTI

Rockwell Medical (RMTI) Stock Price, News & Analysis

$1.66
+0.02 (+1.21%)
(As of 12:31 PM ET)
Today's Range
$1.60
$1.66
50-Day Range
$1.23
$1.71
52-Week Range
$1.16
$6.24
Volume
197,293 shs
Average Volume
229,015 shs
Market Capitalization
$48.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Rockwell Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
329.4% Upside
$7.00 Price Target
Short Interest
Healthy
2.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
0.10mentions of Rockwell Medical in the last 14 days
Based on 23 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.11) to $0.06 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.25 out of 5 stars

Medical Sector

159th out of 939 stocks

Pharmaceutical Preparations Industry

62nd out of 433 stocks

RMTI stock logo

About Rockwell Medical Stock (NASDAQ:RMTI)

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

RMTI Stock Price History

RMTI Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Q4 2023 Rockwell Medical Inc Earnings Call
Rockwell Medical: Q4 Earnings Insights
Rockwell Medical: Q4 Earnings Snapshot
Rockwell Medical earnings preview: what Wall Street is expecting
Rockwell Medical Inc RMTI
Returning To Rockwell Medical: Buy At 65% Of Revenue
See More Headlines
Receive RMTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rockwell Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:RMTI
CUSIP
77437410
Employees
237
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$9.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+324.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-8,440,000.00
Pretax Margin
-10.09%

Debt

Sales & Book Value

Annual Sales
$83.61 million
Cash Flow
$0.02 per share
Book Value
$0.75 per share

Miscellaneous

Free Float
28,690,000
Market Cap
$48.39 million
Optionable
Optionable
Beta
1.16

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Mark Strobeck Ph.D. (Age 53)
    President, CEO & Director
    Comp: $643.41k
  • Ms. Megan C. Timmins (Age 51)
    Executive VP, Chief Legal Officer & Secretary
    Comp: $518.09k
  • Mr. Jesse Neri
    Senior Vice President of Finance
  • Mr. James A. McCarthy
    Senior Vice President of Business & Corporate Development
  • Mr. Timothy T. Chole
    Senior Vice President of Sales & Marketing
  • Ms. Heather R. Hunter
    Senior VP & Chief Corporate Affairs Officer
  • Mr. David J. Kull (Age 56)
    Secretary
  • Mr. Jason Finkelstein
    Investor Relations Representative

RMTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Rockwell Medical stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rockwell Medical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RMTI shares.
View RMTI analyst ratings
or view top-rated stocks.

What is Rockwell Medical's stock price target for 2024?

2 Wall Street research analysts have issued 12-month target prices for Rockwell Medical's shares. Their RMTI share price targets range from $5.00 to $9.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 329.4% from the stock's current price.
View analysts price targets for RMTI
or view top-rated stocks among Wall Street analysts.

How have RMTI shares performed in 2024?

Rockwell Medical's stock was trading at $1.89 on January 1st, 2024. Since then, RMTI stock has decreased by 13.8% and is now trading at $1.63.
View the best growth stocks for 2024 here
.

When is Rockwell Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our RMTI earnings forecast
.

How were Rockwell Medical's earnings last quarter?

Rockwell Medical, Inc. (NASDAQ:RMTI) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.05. The business had revenue of $23.77 million for the quarter, compared to the consensus estimate of $23.67 million. Rockwell Medical had a negative net margin of 10.09% and a negative trailing twelve-month return on equity of 39.17%. During the same quarter in the previous year, the company posted ($0.40) earnings per share.

When did Rockwell Medical's stock split?

Rockwell Medical's stock reverse split before market open on Friday, May 13th 2022. The 1-11 reverse split was announced on Friday, May 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

What guidance has Rockwell Medical issued on next quarter's earnings?

Rockwell Medical issued an update on its FY 2024 earnings guidance on Thursday, March, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $84.0 million-$88.0 million, compared to the consensus revenue estimate of $98.0 million.

What is Robert L. Chioini's approval rating as Rockwell Medical's CEO?

6 employees have rated Rockwell Medical Chief Executive Officer Robert L. Chioini on Glassdoor.com. Robert L. Chioini has an approval rating of 22% among the company's employees. This puts Robert L. Chioini in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rockwell Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rockwell Medical investors own include Immunomedics (IMMU), JinkoSolar (JKS), Seagen (SGEN), Geron (GERN), OPKO Health (OPK), Amarin (AMRN), Gilead Sciences (GILD), ImmunoGen (IMGN), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

Who are Rockwell Medical's major shareholders?

Rockwell Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (6.50%), Vanguard Group Inc. (3.77%), Vanguard Group Inc. (3.77%), Perkins Capital Management Inc. (1.23%), Raymond James & Associates (0.78%) and WealthTrust Axiom LLC (0.11%).
View institutional ownership trends
.

How do I buy shares of Rockwell Medical?

Shares of RMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RMTI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners